A Single-Center, Randomized, Double-Blind Study of 94 Patients Undergoing Surgery for Cerebral Glioma to Compare Postoperative Thromboprophylaxis with and without Rivaroxaban

10 February 2022 : Clinical Research

Zi-Yan Wang^1ABC, You-Dong Wan^2CDEF, Xian-Zhi Liu^1EFG, Hao Wang^1AD, Guang-Yi Jiang^1ABF, Bo Yang^1ABCDEFG*

DOI: 10.12659/MSM.934341

Med Sci Monit 2022; 28:e934341

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Comparison of primary endpoint between rivaroxaban and placebo groups.

Parameter	Rivaroxaban (n=47)	Placebo (n=47)	P value
Venous thromboembolism	1 (2.1%)	10 (21.3%)	0.008^*
Distal deep-vein thrombosis	1 (2.1%)	6 (12.8%)	0.11^*
Proximal deep-vein thrombosis	0	3 (6.4%)
Pulmonary embolism	0	1 (2.1%)
Symptomatic deep-vein thromboses	0	2 (4.2%)
^* Fisher’s exact probability test was used for analysis.

Back to the Article